TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men
... there are certain benefits to menopausal hormone therapy
(HT) in newly postmenopausal women, but that ... risks and a potential loss of benefit to estrogen therapy
in women who have been postmenopausal for several ... interesting because the effects of GH therapy
have not been studied extensively. The body ...
Study Results Show That Minimally Invasive Therapy is Successful for Over Two-Thirds of Stroke Patients Treated Outside the Standard Eight-Hour Window
... invasive endovascular (through the vessel) therapy
made its debut two decades ago, stroke care ... multi-center study shows that endovascular therapy
beyond the eight-hour window restored blood flow ... avenue to pursue. This meant that endovascular therapy
(performed by neurointerventional specialists who ...
Estrogen Getting Cool Reception From Dermatologists for Mixed Results in Improving Appearance of Skin
... -- For many women, hormone replacement therapy
(HRT) can alleviate the physical symptoms ... use and the known risks of prolonged estrogen therapy
-- including an increased risk of breast cancer." ... -- physicians often prescribe hormone replacement therapy
(HRT) to boost the body's estrogen levels that ...
Cyberonics Provides Update on Depression Post-Approval Study
... and treatment-resistant depression. The VNS therapy
System uses a surgically implanted medical device ... to the vagus nerve. Cyberonics markets the VNS therapy
System in selected markets worldwide.
... limited to: continued market acceptance of VNS therapy
and sales of our product; the development and ...
First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center
... This is safer both for patients and for radiation therapy
staff who are able to remain in the room to ... enables clinicians to administer radiation therapy
without the use of a radioactive isotope and in ... of surface cancers or conditions where radiation therapy
is indicated, including IORT (intraoperative ...
FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
... and hydrochlorothiazide) tablets as initial therapy
for patients who are likely to need multiple ...
The FDA approval of Tekturna HCT as initial therapy
was based on clinical trial data involving more ... support the first-line use of combination therapy
in appropriate high blood pressure patients. The ...
New Results From ARTEN Study of Nevirapine Plus Tenofovir and Emtricitabine (TDF/FTC) Versus Boosted Protease Inhibitor Regimen of Atazanavir/Ritonavir Plus TDF/FTC Revealed
... when combined with TDF/FTC, a modern backbone therapy
commonly used with both nevirapine and ATV/r in ... 36) and without subsequent rebound or change of therapy
prior to week 48. In the primary analysis of the ... subsequent rebound or change of antiretroviral therapy
prior to or at week 48.(1) In patients who began ...
Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
... CCR5 antagonist, for use in first-line therapy
of adult treatment-naive HIV-infected patients ... benefit of preserving the current first-line therapy
and subsequent regimens for future use."
... it is recommended as an option for first-line therapy
in both the International AIDS Society and ...
Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
... results help support Asacol HD as an effective therapy
in patients with moderately active UC," said ... with their doctors to determine the course of therapy
that is best for them."
P&GP has been a ... Physicians have relied on Asacol as a trusted UC therapy
for more than 17 years. Asacol HD is the newest ...
Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy
... panel discussion on myoblast (muscle stem cell) therapy
between distinguished physicians and scientists ... (MARVEL) to advance muscle stem cell (myoblast) therapy
for treating heart failure to mainstream use with ... Medicine, discussed the difficulties of stem cell therapy
in scar tissue. "Cells of the myoblast variety ...
Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
... will determine whether tailored antiplatelet therapy
for poor responders, identified based on the ... of variability in response to antiplatelet therapy
has been well established. Also being ... study to determine whether tailored antiplatelet therapy
based on the results of the company's VerifyNow ...
Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
... compulsive disorder is beneficial, but the therapy
needs further study," Dr. Lee says. The potential ... to the review.
Unlike electroshock therapy
(ECT), which stimulates the entire brain, DBS ... 1 in 5 persons.
Medications and psychiatric therapy
can effectively treat many patients with major ...
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
... of Medicine , USA and President of The
Project. "Epilepsy is a devastating condition ... acetate adds
an important new choice of therapy
for patients who are in vital need of
better ... III studies demonstrated that add-on therapy
with once-daily Zebinix(R)
(800mg and 1200mg) was ...
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
... Opinion Recommends Approval of New Anti-TNF therapy
in Three Rheumatic Diseases with Novel ... (golimumab) as a once-monthly, subcutaneous therapy
for the treatment of moderate-to-severe, active ... patients when the response to previous DMARD therapy
has been inadequate. SIMPONI has also been shown ...
Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation
... of minimal residual disease was used to modify therapy
based on the level of disease detected. This ...
St. Jude investigators applied personalized therapy
based on molecular genetics of ALL, ... and senior author of the paper. "Personalized therapy
that we use avoids over- or under-treatment to ...
ALP Life Sciences, LLC Announces Nanoveson(TM) Patent Filing and Whitepaper Availability on Proposed Therapy for Non-Alcoholic Fatty Liver Disease (NAFLD) and Comorbid Diseases
... of self-organizing lipid membranes. Nanoveson(TM) therapy
utilizes only natural compounds. The therapy
triggers liver triglyceride remodeling into bile ... asthma, diabetes and cancer. Nanoveson(TM) therapy
may improve enterohepatic circulation by removing ...
New Therapy Found to Prevent Heart Failure
... received an implanted cardiac resynchronization therapy
device with defibrillator (CRT-D) versus patients ... The new generation of cardiac resynchronization therapy
defibrillators (CRT-Ds) was designed to stop ... from the current study indicate that CRT-D therapy
improves cardiac function and prevents the ...
MADIT-CRT Trial Meets Primary Endpoint
... show Boston Scientific cardiac resynchronization therapy
defibrillators (CRT-Ds) to be associated with a ... early intervention with cardiac resynchronization therapy
can slow the progression of heart failure. It is ... an ICD or CRT-D were first indicated for this therapy
by a clinical trial sponsored by Boston ...
Alfacell Provides Shareholder Update
... remains a viable candidate for second line therapy
The fact that Onconase was able to ... lives of patients who had failed a prior chemo therapy
was not lost in our thoughts. About a year ago, ... In this capacity Onconase can be widely used in therapy
of different tumor types, including most common ...
HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
... investigating an experimental, cell-based wound therapy
---HP802-247---intended for the treatment of ... of the trial protocol. "This is the largest cell therapy
dose ranging trial ever undertaken in the area of ... HEALTHPOINT. "The novel format of this cell-based therapy
shows great potential to deliver a compelling, ...
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
... receiving SIMPONI whose prior anti-TNF-alpha therapy
had been discontinued due to a lack of efficacy ... receiving SIMPONI whose prior anti-TNF-alpha therapy
had been discontinued for all other reasons ... percent of patients received prior anti-TNF-alpha therapy
for at least 12 weeks and 49 percent received ...
Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
... Results from the study entitled, "Tadalafil therapy
for Pulmonary Arterial Hypertension," were ... orally once a day as monotherapy or as add-on therapy
to bosentan. The primary endpoint was change from ... should be avoided. For patients on ADCIRCA therapy
that require treatment with ritonavir, dosage ...
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
... have a high risk of relapse after initial therapy
and no treatments are currently available to ... to remain disease-free. There is no approved therapy
for the approximately 50% of patients who will ... Administration (FDA) as the first oral, daily therapy
(5 mg and 10 mg tablets) to treat advanced kidney ...
SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine
... CAD might be better treated with optimal medical therapy
(OMT) plus either percutaneous coronary ... to a "real-world" patient scenario, where medical therapy
compliance is shown to be a large concern.
... for patients with stable angina, optimal medical therapy
is important as one of the first steps to manage ...
Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
... with exenatide once weekly, an investigational therapy
for type 2 diabetes. These findings were ... loss, compared to BYETTA. If approved, this therapy
could fill an important unmet need for treating ... their blood sugar levels. BYETTA is an add-on therapy
for people currently using metformin, a ...
Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients
... indicate that AFRESA may be a promising new therapy
for patients with type 1 and type 2 diabetes, as ... is a novel, ultra rapid acting mealtime insulin therapy
with an action profile that mimics meal-related ... insulin with/ without oral anti-hyperglycemic therapy
were randomized to a 52-week course of either ...
Boehringer Ingelheim Unveils Diabetes Pipeline
... a measure of blood sugar, when given as add-on therapy
to type 2 diabetes patients inadequately ... regimens are needed so physicians can tailor therapy
to the individual patient needs. We are now ... and safety profile of linagliptin as add-on therapy
in patients with type 2 diabetes who were failing ...
AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
... product comparable to standard insulin therapy
in pulmonary function tests
NEW ORLEANS, ... is a novel, ultra rapid acting mealtime insulin therapy
with an action profile that mimics meal-related ... (type 2 diabetes). Current mealtime insulin therapy
regimens have a number of limitations, including ...
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
... and were assumed to be non-responders to therapy
or not in steroid-free remission at week 50, was ... In 1998, REMICADE became the first anti-TNF-alpha therapy
approved by the FDA for the treatment of ... has also become the first and only anti-TNF-alpha therapy
approved by the FDA for the treatment of ...
Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
... 31, 2009. Results showed that after 12 months of therapy
for continuing patients, 20 percent of Lialda ... of patients who remained on their prescribed therapy
over an extended period of time. The study ...
Results also showed that after 12 months of therapy
for continuing and restart patients, 32 percent ...
Results and Additional Analyses From Study Show That Corthera's Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
... indications that relaxin may be an important new therapy
for patients admitted to hospital with acute ... on the types of patients who might benefit from therapy
with relaxin, as well as the mechanisms by which ... relaxin was administered with standard-of-care therapy
for acute heart failure, relaxin caused rapid, ...
Three Independent Studies Include the ImmuKnow(R) Assay to Manage and Optimize Immunosuppression Therapy in Transplant Patients
... of the ImmuKnow assay to guide immunosuppression therapy
would reduce drug toxicity and drug-related ... "ImmuKnow may lead to improved immunosuppression therapy
management that benefits transplant patients by ... during the management of immunosuppression therapy
was based on ImmuKnow assay levels. In 32 other ...
Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
... Vandetanib is the first oral targeted therapy
to show evidence of clinical benefits when added ... previously treated with one prior anti-cancer therapy
for advanced NSCLC.
Data from ZEAL(2), a ... previously treated with one prior anti-cancer therapy
for advanced NSCLC.
Evaluation of secondary ...
Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
... patients with high-risk melanoma given adjuvant therapy
with granulocyte-macrophage colony stimulating ... Lymphoma
Idiotype vaccine therapy
(BiovaxID) in follicular lymphoma in first ... serious or anaphylactic reactions occur, Leukine therapy
should immediately be discontinued and ...
Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
... by Percutaneous Administration of Gene therapy
in Cardiac Disease (CUPID), a First-in-Human ... at the 12th Annual American Society of Gene therapy
The Phase 1 data showed that ... gene transfer technology, has placed gene-based therapy
for heart failure within reach and yielded ...
New Therapy Enlists Immune System to Boost Cure Rate in a Childhood Cancer
... announced encouraging results for an experimental therapy
using elements of the body's immune system to ... the immunotherapy, while half received standard therapy
(chemotherapy and stem cell transplantation). The ... 20 percent more likely than those in the standard therapy
group to live disease-free two years after ...
Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
... is approved in the US as the first oral, daily therapy
(5 mg and 10 mg tablets) to treat patients with ... should be evaluated prior to the start of therapy
with Afinitor and periodically thereafter. Strong ... reactions, or hematologic adverse reactions. therapy
with Gleevec was discontinued for drug-related ...
AMT Receives EMEA Orphan Drug Designation for Acute Intermittent Porphyria
... has granted Orphan Drug
Designation to AMT's gene therapy
product AMT-021 for the treatment of ... in an animal
model of AIP. In this model, the therapy
completely prevented the occurrence
of attacks ... Therapeutics
AMT has a unique gene therapy
platform that to date appears to circumvent
Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development
... Data show superiority of endoscopic ablation therapy
using the HALO System for eradicating Barrett's ... England Journal of Medicine reveal that ablative therapy
using the HALO system (BARRX Medical, Inc.) is ... 3.3 million Americans. Additionally, ablative therapy
using the HALO system reduced the risk of ...
Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
... drug (AED) is available in the U.S. as an add-on therapy
for the treatment of partial-onset seizures in ... treatment with one drug remains the goal of AED therapy
and provides adequate control to many patients, ... However, some studies indicate that when primary therapy
is well-tolerated, but does not provide adequate ...